Prognostic Value of Systemic Immune-inflammation Index in Cancer: A Meta-analysis

Overview

Journal J Cancer

Specialty Oncology

Date 2018 Oct 2

PMID 30271489

Citations 177

Authors

Ruonan Yang

Qian Chang

Xianchun Meng

Nan Gao

Wanhai Wang

Affiliations

Soon will be listed here.

Abstract

Systemic immune-inflammation index (SII), on the basis of lymphocyte, neutrophil and platelet counts had been published to be a good prognostic factor in multiple cancers. Nevertheless, the prognostic value of SII in cancer patients remains inconsistent. Therefore, we carried out a meta-analysis to evaluate the prognostic value of SII in these patients with cancer. A total of 22 articles with 7657 patients enrolled in this meta-analysis. The combined result revealed that a high SII was evidently correlated with poor overall survival (OS) (HR=1.69, 95%CI=1.42-2.01, <0.001), poor time to recurrent (TTR) (HR=1.87, <0.001) , poor progress-free survival (PFS) (HR=1.61, =0.012) ,poor cancer-specific survival (CSS) (HR=1.44, =0.027) , poor relapse-free survival (RFS) (HR=1.66, =0.025) and poor disease-free survival (DFS) (HR=2.70, <0.001) in patients with cancers. Subgroup analysis indicated that SII over the cutoff value could predict worse overall survival in Hepatocellular carcinoma (<0.001), Gastric cancer (=0.005), Esophageal Squamous Cell Carcinoma (=0.013), Urinary system cancer (<0.001), Small cell lung cancer (<0.001), Non-Small cell lung cancer (<0.001) and Acral Melanoma (<0.001). The largest effect size was observed in the Hepatocellular carcinoma (HR=2.11). In addition, these associations did not vary significantly by the cutoff value, sample size and ethnicity. Therefore, high SII may be a potential prognostic marker in patients with various cancers and associated with the poor overall outcomes.

Citing Articles

Association between TyG-BMI and early-onset hypertension: evidence from NHANES.

Li W, Ge C, Zhou J Sci Rep. 2025; 15(1):8595.

PMID: 40074808 PMC: 11903749. DOI: 10.1038/s41598-025-92159-6.

Association between the systemic immune-inflammation index and metabolic syndrome and its components: results from the multi-ethnic study of atherosclerosis (MESA).

Ramezankhani A, Tohidi M, Hadaegh F Cardiovasc Diabetol. 2025; 24(1):78.

PMID: 39955525 PMC: 11830208. DOI: 10.1186/s12933-025-02629-4.

Serum Galectin-3 and IL-6 as Inflammatory Markers in Bipolar Disorder: Insights from Manic and Euthymic Episodes.

Ozkaya A, Gurbuzer N, Tozoglu E, Akyildirim S, Mercantepe F J Clin Med. 2025; 14(3).

PMID: 39941474 PMC: 11818607. DOI: 10.3390/jcm14030803.

Association between neutrophil percentage to albumin ratio and short term prognosis of acute on chronic liver failure treated with artificial liver support system.

Ma Y, Du L, Bai L, Tang H Sci Rep. 2025; 15(1):5042.

PMID: 39934390 PMC: 11814120. DOI: 10.1038/s41598-025-89832-1.

Association between the immune-inflammation indicators and osteoarthritis - NHANES 1999-2018.

Xue Y, Chang C, Chen Y, Jia L, Wang H, Liu Z Osteoarthr Cartil Open. 2025; 7(1):100453.

PMID: 39802080 PMC: 11720436. DOI: 10.1016/j.ocarto.2024.100453.

References

Yang J, Guo X, Wang M, Ma X, Ye X, Lin P . Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS. Sci Rep. 2017; 7(1):17166. PMC: 5719445. DOI: 10.1038/s41598-017-17130-6. View

Liu X, Sun X, Liu J, Kong P, Chen S, Zhan Y . Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer. Transl Oncol. 2015; 8(4):339-45. PMC: 4562973. DOI: 10.1016/j.tranon.2015.06.006. View

Ostan R, Lanzarini C, Pini E, Scurti M, Vianello D, Bertarelli C . Inflammaging and cancer: a challenge for the Mediterranean diet. Nutrients. 2015; 7(4):2589-621. PMC: 4425163. DOI: 10.3390/nu7042589. View

Huang Q, Zhou L, Zeng W, Ma Q, Wang W, Zhong M . Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Cell Physiol Biochem. 2017; 41(6):2411-2418. DOI: 10.1159/000475911. View

Hu B, Yang X, Xu Y, Sun Y, Sun C, Guo W . Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014; 20(23):6212-22. DOI: 10.1158/1078-0432.CCR-14-0442. View

Lolli C, Caffo O, Scarpi E, Aieta M, Conteduca V, Maines F . Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Front Pharmacol. 2016; 7:376. PMC: 5062111. DOI: 10.3389/fphar.2016.00376. View

Zheng Z, Zhou L, Gao S, Yang Z, Yao J, Zheng S . Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis. Int J Med Sci. 2013; 10(6):653-64. PMC: 3619114. DOI: 10.7150/ijms.6050. View

Zheng L, Zou K, Yang C, Chen F, Guo T, Xiong B . Inflammation-based indexes and clinicopathologic features are strong predictive values of preoperative circulating tumor cell detection in gastric cancer patients. Clin Transl Oncol. 2017; 19(9):1125-1132. DOI: 10.1007/s12094-017-1649-7. View

Wang B, Tian L, Gao X, Ma X, Wu J, Zhang C . Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection. Clin Chem Lab Med. 2016; 54(12):1963-1969. DOI: 10.1515/cclm-2015-1191. View

10.

Gao X, Tian L, Wu J, Ma X, Zhang C, Zhou Y . Circulating CD14 HLA-DR myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. Hepatol Res. 2016; 47(10):1061-1071. DOI: 10.1111/hepr.12831. View

11.

Chen J, Zhai E, Yuan Y, Wu K, Xu J, Peng J . Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017; 23(34):6261-6272. PMC: 5603492. DOI: 10.3748/wjg.v23.i34.6261. View

12.

Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D . Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget. 2016; 7(41):67142-67149. PMC: 5341863. DOI: 10.18632/oncotarget.11565. View

13.

Mezouar S, Frere C, Darbousset R, Mege D, Crescence L, Dignat-George F . Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences. Thromb Res. 2016; 139:65-76. DOI: 10.1016/j.thromres.2016.01.006. View

14.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

15.

Yang Z, Zhang J, Lu Y, Xu Q, Tang B, Wang Q . Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization. Oncotarget. 2015; 6(40):43090-8. PMC: 4767493. DOI: 10.18632/oncotarget.5719. View

16.

Conroy G, Salleron J, Belle A, Bensenane M, Nani A, Ayav A . The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib. Oncotarget. 2017; 8(56):95853-95864. PMC: 5707066. DOI: 10.18632/oncotarget.21401. View

17.

Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q . Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. Tohoku J Exp Med. 2015; 236(4):297-304. DOI: 10.1620/tjem.236.297. View

18.

Lolli C, Basso U, Derosa L, Scarpi E, Sava T, Santoni M . Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget. 2016; 7(34):54564-54571. PMC: 5342364. DOI: 10.18632/oncotarget.10515. View

19.

Zhou W, Wu J, Li X, Wang Q, Ni X, Jiang J . [Effect of preoperative monocyte-lymphocyte ratio on prognosis of patients with resectable esophagogastric junction cancer]. Zhonghua Zhong Liu Za Zhi. 2017; 39(3):178-183. DOI: 10.3760/cma.j.issn.0253-3766.2017.03.004. View

20.

Yu J, Wu X, Yu H, Li S, Mao L, Chi Z . Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon. Transl Oncol. 2017; 10(5):719-725. PMC: 5510521. DOI: 10.1016/j.tranon.2017.06.004. View